Involvement of the Janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis

Journal of Interferon and Cytokine Research

Volumn 34, Issue 8, 2014, Pages 577-588

  Benveniste, Etty N ^a   Liu, Yudong ^a   McFarland, Braden C ^a   Qin, Hongwei ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DERIVATIVE; GAMMA INTERFERON; GLATIRAMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; LAQUINIMOD; STAT PROTEIN; ANTIINFLAMMATORY AGENT; CYTOKINE; ENZYME INHIBITOR;

ADAPTIVE IMMUNITY; ANIMAL MODEL; AUTOIMMUNE DISEASE; AXONAL INJURY; BIOLOGICAL ACTIVITY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETIC TRANSCRIPTION; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROGENIC INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; HUMANS; JANUS KINASES; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; NEUROGENIC INFLAMMATION; OLIGODENDROGLIA; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84905373815     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0012     Document Type: Review

References (122)

1. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. 2011. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14(9):1142-1149.
2. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. 2010. T helper type 1 and 17 cells determine efficacy of interferonbeta in multiple sclerosis and experimental encephalomyeli-tis. Nat Med 16(4):406-412.
3. Bailey-Bucktrout SL, Caulkins SC, Goings G, Fischer JA, Dzionek A, Miller SD. 2008. Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis. J Immunol 180(10):6457-6461.
4. Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D, Wu W, Uitdehaag BM, Kappos L, Polman CH, Matthews PM, Hauser SL, Gibson RA, Oksenberg JR, Barnes MR. 2009. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet 18(11):2078-2090.
5. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, RA O'Connor, Anderton SM, Bar-Or A, Fillatreau S, Gray D. 2012. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209(5):1001-1010.
6. Basu R, Hatton RD, Weaver CT. 2013. The Th17 family: flexibility follows function. Immunol Rev 252(1):89-103.
7. Becher B, Segal BM. 2011. T(H)17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol 23(6):707-712.
8. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemp-pinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hint-zen R, Barcellos LF, Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Sondergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Berga-maschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelcic I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppa V, Liberatore G, Lie BA, Lill CM, Linden M, Link J, Luessi F, Lycke J, Macciardi F, Mannisto S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45(11):1353-1360.
9. Berard JL, Kerr BJ, Johnson HM, David S. 2010. Differential expression of SOCS1 in macrophages in relapsing-remitting and chronic EAE and its role in disease severity. Glia 58(15):1816.
10. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchroo VK. 2004. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalo-myelitis. J Exp Med 200(1):79-87.
11. Bhat R, Steinman L. 2009. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 64(1):123-132.
12. Block ML, Zecca L, Hong JS. 2007. Microglia-mediated neu-rotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8(1):57-69.
13. Brantley E, Benveniste EN. 2008. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6(5):675-684.
14. Bright JJ, Du C, Sriram S. 1999. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus Kinase-2 and prevents experimental allergic encephalomy-elitis. J Immunol 162(10):6255-6262.
15. Bronson PG, Caillier S, Ramsay PP, McCauley JL, Zuvich RL, De Jager PL, Rioux JD, Ivinson AJ, Compston A, Hafler DA, Sawcer SJ, Pericak-Vance MA, Haines JL, Hauser SL, Ok-senberg JR, Barcellos LF. 2010. CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. Hum Mol Gen 19(11):2331-2340.
16. Cassol E, Cassetta L, Alfano M, Poli G. 2010. Macrophage polarization and HIV-1 infection. J Leukoc Biol 87(4):599-608.
17. Chen C, Liu X, Wan B, Zhang JZ. 2009. Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation. J Immunol 183(1):246-253.
18. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ. 2006. Selective regulatory function of SOCS3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103: 8137-8142.
19. Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, Khoury SJ. 2001. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 108(5): 739-747.
20. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. 2011. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12(6):560-567.
21. Couturier N, Bucciarelli F, Nurtdinov RN, Debouverie M, Lebrun-Frenay C, Defer G, Moreau T, Confavreux C, Vukusic S, Cournu-Rebeix I, Goertsches RH, Zettl UK, Comabella M, Montalban X, Rieckmann P, Weber F, Muller-Myhsok B, Edan G, Fontaine B, Mars LT, Saoudi A, Oksenberg JR, Clanet M, Liblau RS, Brassat D. 2011. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 134(Pt 3):693-703.
22. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Rama-gopalan SV. 2012. The evidence for a role of B cells in multiple sclerosis. Neurology 78(11):823-832.
23. Domingues HS, Mues M, Lassmann H, Wekerle H, Krishna-moorthy G. 2010. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encepha-lomyelitis. PLoS One 5(11):e15531.
24. Egwuagu CE, Larkin J. 2013. Therapeutic targeting of STAT pathways in CNS autoimmune diseases. JAK-STAT 2(1): e24134.
25. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, Zhang GX, Dittel BN, Rostami A. 2011. The encephalitogenicity of T(H)17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12(6): 568-575.
26. Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam PS. 2004. Characterization of a peptide inhibitor of Janus Kinase 2 that mimics Suppressor Of Cytokine Signaling 1 function. J Immunol 172(12):7510-7518.
27. Frank DA. 2012. Targeting STATS for cancer therapy: "un- druggable" no more. JAK-STAT 1(4):261-262.
28. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K. 2010. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184(9):5298-5307.
29. Frisullo G, Angelucci F, Caggiula M, Nociti V, Iorio R, Pata-nella AK, Sancricca C, Mirabella M, Tonali PA, Batocchi AP. 2006. P-STAT1, P-STAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J Neurosci Res 84(5):1027-1036.
30. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Mirabella M, Tonali PA, Batocchi AP. 2008. The persistency of high levels of P-STAT3 expression in circulating CD4+T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. J Neuroimmunol 205(1-2):126-134.
31. Galli SJ, Borregaard N, Wynn TA. 2011. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 12(11):1035-1044.
32. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. 2010a. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 10(6):453-460.
33. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. 2010b. Development of monocytes, macrophages, and dendritic cells. Science 327(5966):656-661.
34. Gensel JC, Nakamura S, Guan Z, van Rooijen N, Ankeny DP, Popovich PG. 2009. Macrophages promote axon regeneration with concurrent neurotoxicity. J Neurosci 29(12):3956-3968.
35. Ghoreschi K, Bruck J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Rocken M. 2011a. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11):2291-2303.
36. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. 2011b. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J Immunol 186(7):4234-4243.
37. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3(1):23-35.
38. Goverman J. 2009. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9(6):393-407.
39. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albe-siano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau F, Yu H, Pardoll DM, Drake CG. 2007. Cutting edge: an in vivo requirement for STAT3 signaling in Th17 development and Th17-dependent autoimmunity. J Immunol 179(7):4313-4317.
40. Hauser SL, Chan JR, Oksenberg JR. 2013. Multiple sclerosis: prospects and promise. Ann Neurol 74(3):317-327.
41. IMSGC. 2013. Network-Based multiple sclerosis pathway analysis with GWAS data from 15, 000 cases and 30, 000 controls. Am J Hum Genet 92(6):854-865.
42. Jager LD, Dabelic R, Waiboci LW, Lau K, Haider MS, Ahmed CM, Larkin J 3rd, David S, Johnson HM. 2011. The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic en-cephalomyelitis. J Neuroimmunol 232(1-2):108-118.
43. Jakkula E, Leppa V, Sulonen AM, Varilo T, Kallio S, Kemp-pinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttila T, Reunanen M, Aromaa A, Oturai AB, Sondergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L. 2010. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Gen 86(2):285-291.
44. Jia Y, Jing J, Bai Y, Li Z, Liu L, Luo J, Liu M, Chen H. 2011. Amelioration of experimental autoimmune encephalomyelitis by plumbagin through down-regulation of JAK-STAT and NF-kappaB signaling pathways. PLoS One 6(10):e27006.
45. Jin W, Zhou XF, Yu J, Cheng X, Sun SC. 2009. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood 113(26):6603-6610.
46. Kershaw NJ, Murphy JM, Lucet IS, Nicola NA, Babon JJ. 2013. Regulation of Janus Kinases by SOCS proteins. Biochem Soc Trans 41(4):1042-1047.
47. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M, Udalova IA. 2011. IRF5 promotes inflammatory macrophage polarization and Th1-Th17 responses. Nat Immunol 12(3):231-238.
48. Kroenke MA, Chensue SW, Segal BM. 2010. EAE mediated by a non-IFN-gamma/non-IL-17 pathway. Eur J Immunol 40(8): 2340-2348.
49. Kuchroo VK, Ohashi PS, Sartor RB, Vinuesa CG. 2012. Dys-regulation of immune homeostasis in autoimmune diseases. Nat Med 18(1):42-47.
50. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS. 2011. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 25(5):401-414.
51. Lee SW, Choi H, Eun SY, Fukuyama S, Croft M. 2011. Nitric oxide modulates TGF-b-directive signals to suppress Foxp3 + regulatory T cell differentiation and potentiate Th1 development. J Immunol 186(12):6972-6980.
52. Li Y, Chu N, Rostami A, Zhang GX. 2006. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 pheno-type that directs Type 2 Th cell differentiation in vitro and in vivo. J Immunol 177(3):1679-1688.
53. Lill CM, Schjeide BM, Akkad DA, Blaschke P, Winkelmann A, Gerdes LA, Hoffjan S, Luessi F, Dorner T, Li SC, Steinha-gen-Thiessen E, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kumpfel T, Kubisch C, Epplen JT, Zettl UK, Bertram L, Zipp F. 2012. Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. Neurogenetics 13(1):83-86.
54. Linker RA, Lee DH. 2009. Models of autoimmune demyelin-ation in the central nervous system: on the way to transla-tional medicine. Exp Transl Stroke Med 1:5.
55. Liu X, Lee YS, Yu CR, Egwuagu CE. 2008. Loss of STAT3 in CD4 + T cells prevents development of experimental autoimmune diseases. J Immunol 180(9):6070-6076.
56. Liu Y, Holdbrooks AT, De Sarno P, Rowse AL, Yanagisawa LL, McFarland BC, Harrington LE, Raman C, Sabbaj S, Benve-niste EN, Qin H. 2014. Therapeutic efficacy of suppressing the JAK/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol 192:59-72.
57. Lopez-Diego RS, Weiner HL. 2008. Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 7(11):909-925.
58. Mantovani A, Sica A, Locati M. 2005. Macrophage polarization comes of age. Immunity 23(4):344-346.
59. Mantovani A, Sica A, Locati M. 2007. New vistas on macrophage differentiation and activation. Eur J Immunol 37(1):14-16.
60. Mayo L, Quintana FJ, Weiner HL. 2012. The innate immune system in demyelinating disease. Immunol Rev 248(1): 170-187.
61. McFarland BC, Hong SW, Rajbhandari R, Twitty GB Jr., Gray GK, Yu H, Benveniste EN, Nozell SE. 2013. NF-kappaB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One 8(11):1-12.
62. McGeachy MJ. 2011. GM-CSF: the secret weapon in the Th17 arsenal. Nat Immunol 12(6):521-522.
63. McMurray JS, Mandal PK, Liao WS, Klostergaard J, Robertson FM. 2012. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyr-osine705 phosphorylation by phosphopeptide mimetic pro-drugs targeting the Src homology 2 (SH2) domain. JAKSTAT 1(4):263-347.
64. Miklossy G, Hilliard TS, Turkson J. 2013. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 12(8):611-629.
65. Mildner A, Mack M, Schmidt H, Bruck W, Djukic M, Zabel MD, Hille A, Priller J, Prinz M. 2009. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132(Pt 9):2487-2500.
66. Mujtaba MG, Flowers LO, Patel CB, Patel RA, Haider MI, Johnson HM. 2005. Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J Immunol 175:5077-5086.
67. Muthian G, Bright JJ. 2004. Quercetin, a flavonoid phytoes-trogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J Clin Immunol 24(5):542-552.
68. Muthian G, Raikwar HP, Johnson C, Rajasingh J, Kalgutkar A, Marnett LJ, Bright JJ. 2006. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 26(1):73-85.
69. Nair A, Frederick TJ, Miller SD. 2008. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 65(17):2702-2720.
70. Natarajan C, Bright JJ. 2002. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic en-cephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 3(2):59-70.
71. Nelson EA, Sharma SV, Settleman J, Frank DA. 2011. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget 2(6):518-524.
72. Oksenberg JR, Baranzini SE. 2010. Multiple sclerosis genetics- is the glass half full, or half empty? Nat Rev Neurol 6(8): 429-437.
73. Oksenberg JR, Hauser SL. 2011. Decoding multiple sclerosis. Ann Neurol 70(6):A5-A7.
74. Opar A. 2010. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 9(4):257-258.
75. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. 2013a. Janus Kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72 Suppl 2:111-115.
76. O'Shea JJ, Laurence A, McInnes IB. 2013b. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 9(3):173-182.
77. O'Shea JJ, Plenge R. 2012. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36(4):542-550.
78. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. 2007. GM-CSF production by auto-reactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalo-myelitis. J Immunol 178(1):39-48.
79. Qin H, Holdbrooks AT, Liu Y, Reynolds SL, Yanagisawa LL, Benveniste EN. 2012a. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol 189(7): 3439-3448.
80. Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, Reynolds SL, Weaver CT, Roarty K, Serra R, Benveniste EN, Cong Y. 2009. TGF-b promotes Th17 cell development through inhibition of SOCS3. J Immunol 183(1):97-105.
81. Qin H, Yeh W-I, De Sarno P, Holdbrooks AT, Liu Y, Mul-downey MT, Reynolds SL, Yanagisawa LL, Fox TH III, Park K, Harrington LE, Raman C, Benveniste EN. 2012b. Signal transducer and activator of transcription-3/suppressor of cy-tokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc Natl Acad Sci USA 109(13):5004-5009.
82. Qin X, Guo BT, Wan B, Fang L, Lu L, Wu L, Zang YQ, Zhang JZ. 2010. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J Immunol 185(3): 1855-1863.
83. Quintana A, Muller M, Frausto RF, Ramos R, Getts DR, Sanz E, Hofer MJ, Krauthausen M, King NJ, Hidalgo J, Campbell IL. 2009. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 183(3):2079-2088.
84. Ramgolam VS, Markovic-Plese S. 2011. Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis. J Signal Transduct 2011:635721.
85. Ransohoff RM. 2009. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31(5):711-721.
86. Rivest S. 2009. Regulation of innate immune responses in the brain. Nat Rev Immunol 9(6):429-439.
87. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, De-bouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronc-zynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jan-kowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359):214-219.
88. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. 2011. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813(5):878-888.
89. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS. 2012. Laqui-nimod, a quinoline-3-carboxamide, induces Type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 7(3):1-10.
90. Seavey MM, Dobrzanski P. 2012. The many faces of Janus Kinase. Biochem Pharmacol 83(9):1136-1145.
91. Sen M, Grandis JR. 2012. Nucleic acid-based approaches to STAT inhibition. JAK-STAT 1(4):285-291.
92. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. 2012. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy. Cancer Discov 2(8): 694-705.
93. Shechter R, London A, Varol C, Raposo C, Cusimano M, Yovel G, Rolls A, Mack M, Pluchino S, Martino G, Jung S, Schwartz M. 2009. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 6(7):e1000113.
94. Stark JL, Cross AH. 2006. Differential expression of suppressors of cytokine signaling-1 and-3 and related cytokines in central nervous system during remitting versus non-remitting forms of experimental autoimmune encephalomyelitis. Int Immunol 18(2):347-353.
95. Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, Bassil R, Croci DO, Cerliani JP, Delacour D, Wang Y, Elyaman W, Khoury SJ, Rabinovich GA. 2012. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 37(2):249-263.
96. Steinman L. 2010. Mixed results with modulation of Th-17 cells in human autoimmune diseases. Nat Immunol 11(1):41-44.
97. Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM. 2011. A highly selective, orally active inhibitor of Janus Kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthr Res Ther 13(2):R68.
98. Thone J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R. 2012. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180(1):267-274.
99. Timofeeva OA, Tarasova NI. 2012. Alternative ways of modulating JAK-STAT pathway: looking beyond phosphoryla-tion. JAK-STAT 1(4):274-284.
100. Vandenbroeck K. 2012. Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies. J Interferon Cytokine Res 32(4):139-151.
101. Vandenbroeck K, Alvarez J, Swaminathan B, Alloza I, Mate-sanz F, Urcelay E, Comabella M, Alcina A, Fedetz M, Ortiz MA, Izquierdo G, Fernandez O, Rodriguez-Ezpeleta N, Matute C, Caillier S, Arroyo R, Montalban X, Oksenberg JR, Antiguedad A, Aransay A. 2012. A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes Immun 13(1):21-28.
102. van der Does AM, Beekhuizen H, Ravensbergen B, Vos T, Ot-tenhoff TH, van Dissel JT, Drijfhout JW, Hiemstra PS, Nibbering PH. 2010. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol 185(3):1442-1449.
103. Walker SR, Frank DA. 2012. Screening approaches to generating STAT inhibitors: allowing the hits to identify the targets. JAK-STAT 1(4):292-299.
104. Walker SR, Xiang M, Frank DA. 2013. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol 382(1):616-621.
105. Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, Liang YM, Han H. 2010. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 70(12):4840-4049.
106. Weaver CT, Hatton RD, Mangan PR, Harrington LE. 2007. IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Ann Rev Immunol 25: 821-852.
107. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stuve O, Sobel RA, Steinman L, Zamvil SS. 2007a. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13(8): 935-943.
108. Weber MS, Steinman L, Zamvil SS. 2007b. Statins-treatment option for central nervous system autoimmune disease? Neurotherapeutics 4(4):693-700.
109. Weiner HL. 2008. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 255 Suppl 1:3-11.
110. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. 2007. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282(13):9358-9363.
111. Yogev N, Frommer F, Lukas D, Kautz-Neu K, Karram K, Ielo D, von Stebut E, H.-Probst C, van den Broek M, Riethmacher D, Birnberg T, Blank T, Reizis B, Korn T, Wiendl H, Jung S, Prinz M, Kurschus FC, Waisman A. 2012. Dendritic cells ameliorate autoimmunity in the CNS by controlling the ho-meostasis of PD-1 receptor+regulatory T cells. Immunity 37(2):264-275.
112. Yoshimura A, Suzuki M, Sakaguchi R, Hanada T, Yasukawa H. 2012. SOCS, inflammation, and autoimmunity. Front Immunol 3(20):1-9.
113. Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE. 2012. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS One 7(1):e29742.
114. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798-809.
115. Zaheer S, Wu Y, Bassett J, Yang B, Zaheer A. 2007. Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Neurochem Res 32(12):2123-2131.
116. Zamvil SS, Steinman L. 2002. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 59(7):970-971.
117. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. 2008. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+lymphocytes. J Immunol 180(10):6988-6996.
118. Zhang X, Tao Y, Troiani L, Markovic-Plese S. 2011. Simvas-tatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4 + T cells derived from patients with multiple sclerosis. J Immunol 187(6):3431-3437.
119. Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S. 2013. Simvastatin inhibits secretion of Th17-polarizing cy-tokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Eur J Immunol 43(1): 281-289.
120. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Pa-ladino D, Zhao J, Chen Y, Gunning PT, Turkson J. 2012. Orally bioavailable small-molecule inhibitor of transcription factor STAT3 regresses human breast and lung cancer xe-nografts. Proc Natl Acad Sci USA 109(24):9623-9628.
121. Zhu B, Kennedy JK, Wang Y, Sandoval-Garcia C, Cao L, Xiao S, Wu C, Elyaman W, Khoury SJ. 2011. Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J Immunol 187(5): 2418-2432.
122. Zuvich RL, Bush WS, McCauley JL, Beecham AH, De Jager PL, Ivinson AJ, Compston A, Hafler DA, Hauser SL, Sawcer SJ, Pericak-Vance MA, Barcellos LF, Mortlock DP, Haines JL. 2011. Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex. Hum Mol Gen 20(17):3517-3524.